CSL

Today, we broke ground on a $1.5 billion investment to expand our plasma manufacturing capacity in Kankakee, Illinois. Read how this will support the production of plasma-derived therapies and create new jobs in the US: newsroom.csl.com/2026-03-09-CSL… #CSL #PlasmaDerivedTherapies #RareDisease

Today we announced our half‑year results. Read the full ASX announcement for details: bit.ly/4tzf89M #CSL

Today we’ve announced that Gordon Naylor has been appointed interim Chief Executive Officer and Managing Director, following Dr Paul McKenzie’s decision to retire. Read more: bit.ly/46DKj9K

Today, we announced an upcoming $1.5b in future U.S. capital investments, further strengthening our contribution to the U.S. healthcare ecosystem. This expansion builds on our significant U.S. presence and over $3b invested since 2018. This investment will generate hundreds of high-quality American jobs and substantially bolster U.S. manufacturing for critical plasma-derived therapies. Our goal is to meet the growing clinical need for these life-saving medicines, which are often the sole effective treatments for many rare and serious diseases. We are proud to continue investing in American innovation and talent. newsroom.csl.com/2025-11-18-CSL… #CSL #USManufacturing #PlasmaDerivedTherapies #HealthcareInnovation #AmericanJobs

October is #PlasmaAwarenessMonth, an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients. Our plasma-derived therapies are made possible by the donation of plasma, and these therapies are used to help treat certain serious and rare conditions, including immune deficiencies and bleeding disorders. In certain medical situations, plasma-derived products may also be used in trauma care and maternal health. We encourage everyone to learn more about the #PowerofPlasma, to share the message, and consider becoming a donor themselves. Learn more here: csl.com/we-are-csl/our… #CSLPlasma #PlasmaAwarenessMonth #DonatePlasma

Today we shared our full-year results for FY25. Take a look at some of the key financial and operational highlights. For more details visit our Investor Centre: investors.csl.com #CSL #FullYearResults

The first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of #HAE has been authorized by Health Canada, offering those living with HAE a convenient administration approach. Read more: bit.ly/46MYCtN

Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now. bit.ly/466kBez

Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community. bit.ly/4jZZuOH

@CSL Behring exemplifies the enduring #partnership between Australia and Switzerland, merging Australian #innovation with Swiss precision. It was a pleasure to attend the 25th Anniversary of CSL Behring celebrations in Bern yesterday. @CSLVifor

The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more: bit.ly/3FFkoEI.

Dr @qizhang85 from @SAiGENCI, @UniofAdelaide is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3FxGI2Z

.@DrClareWeeden from @WEHI_research is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3SmhVS7 #CSL

Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years. bit.ly/4mcIkzk

Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs. bit.ly/4cLXPKw

CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at @NATAforum. We look forward to welcoming you on Thursday 24 April at 12:15 CET!

Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more: bit.ly/4bqvtVD

The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.

Along with our partner @ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more: bit.ly/47HgF1z.

Our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE is approved by the EC. We are committed to advancing care for people living with HAE, a community we have supported for over 40 years. Read more: bit.ly/47HgF1z.